Coexpression of hypoxia-inducible factor-1α and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients

Histopathology

Volumn 58, Issue 7, 2011, Pages 1136-1147

  Eckert, Alexander W ^a   Lautner, Matthias H W ^a   Schütze, Andreas ^a   Taubert, Helge ^c   Schubert, Johannes ^a   Bilkenroth, Udo ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Institute of Pathology   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Glucose transporter 1; Head and neck cancer; Hypoxia inducible factor 1 ; Oral squamous cell carcinoma

Indexed keywords

GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; GERMANY; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79959688925     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03806.x     Document Type: Article

References (40)

1. Rogers SN, Brown JS, Wolgaar JA et al. Survival following primary surgery for oral cancer. Oral Oncol. 2009; 45; 201-211.
2. Lothaire P, Azambuja E, Dequanter D et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 2006; 28; 256-269.
3. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26; 225-239.
4. Brahimi-Horn C, Pouysségur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull. Cancer 2006; 93E; 73-80.
5. Semenza GL. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003; 3; 721-732.
6. Brahimi-Horn C, Pouysségur J. Oxygen, a source of life and stress. FEBS Lett. 2007; 581; 3582-3591.
7. Brennan PA, Mackenzie N, Quintero M. Hypoxia-inducible factor 1α in oral cancer. J. Oral Pathol. Med. 2005; 34; 385-389.
8. Wang GL, Jiang B-H, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 1995; 92; 5510-5514.
9. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 1995; 270; 1230-1237.
10. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008; 15; 678-685.
11. Aebershold DM, Burri P, Beer KT et al. Expression of hypoxia-inducible factor 1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001; 61; 2911-2916.
12. Koukourakis MI, Giatromanolaki A, Sivridis E et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002; 53; 1192-1202.
13. Winter SC, Shah KA, Han C et al. The relation between hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006; 107; 757-766.
14. Schrijvers ML, van der Laan BF, de Bock GH et al. Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2008; 72; 161-169.
15. Uehara M, Sano K, Ikeda H, Nonaka M, Asahina I. Hypoxia-inducible factor 1 alpha in oral squamous cell carcinoma and its relation to prognosis. Oral Oncol. 2009; 45; 241-246.
16. Roh S-H, Cho K-J, Kwon GY et al. The prognostic value of hypoxia markers in t2-staged oral tongue cancer. Oral Oncol. 2009; 45; 63-68.
17. Beasley NJP, Leek R, Alam M et al. Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002; 62; 2493-2497.
18. Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, Burger H. HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 2005; 5; 84.
19. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an invivo study. Cancer Lett. 2005; 225; 297-304.
20. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 2004; 4; 891-899.
21. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members. Mol. Membr. Biol. 2001; 18; 247-256.
22. Joost HG, Bell GI, Best JD et al. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am. J. Physiol. Endocrinol. Metab. 2002; 282; 974-976.
23. Mueckler M, Caruso C, Baldwin SA et al. Sequence and structure of a human glucose transporter. Science 1985; 229; 941-945.
24. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007; 53; 233-256.
25. Merrall NW, Plevin R, Gould GW. Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell. Signal. 1993; 5; 667-675.
26. Jonathan RA, Wijffels KI, Peeters W et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother. Oncol. 2006; 79; 288-297.
27. Kunkel M, Morgel M, Stockinger M et al. Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol. 2007; 43; 796-803.
28. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 2005; 5; 42.
29. Eckert AW, Lautner MHW, Taubert H, Schubert J, Bilkenroth U. Expression of GLUT-1 is a prognostic marker for oral squamous cell carcinoma patients. Oncol. Rep. 2008; 20; 1381-1385.
30. Dellas K, Bache M, Pigorsch SU et al. Prognostic impact of HIF-1α expression in patients with definitive radiotherapy for cervical cancer. Strahlenther. Onkol. 2008; 184; 169-174.
31. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8; 138-140.
32. Koukourakis MI, Bentzen SM, Giatromanolaki A et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J. Clin. Oncol. 2006; 24; 727-735.
33. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008; 13; 21-26.
34. Denko NC. Hypoxia, HIF 1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 2008; 8; 705-713.
35. Axelson H, Fredlund E, Ovenberger M, Landberg G, Påhlman S. Hypoxia-induced dedifferentiation of tumor cells-a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin. Cell Dev. Biol. 2005; 16; 554-563.
36. Zhang CP, Zhu LL, Zhao T et al. Characteristics of neural stem cells expanded in lowered oxygen and the potential role of hypoxia-inducible factor-1Alpha. Neurosignals 2007; 15; 259-265.
37. Ma T, Grayson WL, Fröhlich M, Vunjak-Novakovic G. Hypoxia and stem cell-based engineering of mesenchymal tissues. Biotechnol. Prog. 2009; 25; 32-42.
38. Theus MH, Wei L, Cui L et al. Invitro hypoxic preconditioning of embryonic stem cells as a strategy of promoting cell survival and functional benefits after transplantation into the ischemic rat brain. Exp. Neurol. 2008; 210; 656-670.
39. Lee SH, Heo JS, Han HJ. Effect of hypoxia on 2-deoxyglucose uptake and cell cycle regulatory protein expression of mouse embryonic stem cells: involvement of Ca2+/PKC, MAPKs and HIF-1alpha. Cell Physiol. Biochem. 2007; 19; 269-282.
40. Zhao T, Zhang CP, Liu ZH et al. Hypoxia-driven proliferation of embryonic neural stem/progenitor cells-role of hypoxia-inducible transcription factor-1alpha. FEBS J. 2008; 275; 824-834.